Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, Rival P, Devaud C, Prades C, Bouchard H, Cassé A, Henry C, Amara C, Brillac C, Ferrari P, Maçon L, Lacoste E, Combeau C, Beys E, Naimi S, García-Echeverría C, Mayaux JF, Blanc V.
Decary S, et al. Among authors: macon l.
Clin Cancer Res. 2020 Dec 15;26(24):6589-6599. doi: 10.1158/1078-0432.CCR-19-4051. Epub 2020 Oct 12.
Clin Cancer Res. 2020.
PMID: 33046521